ASX 200 Health Care Stock Surges: Strong FY26 Profit, Dividend Growth, FY27 Outlook
Source: Kapitales Research
Fisher & Paykel Healthcare Corporation Limited (ASX: FPH) reported strong FY26 results, supported by double-digit revenue growth, margin expansion, and a higher dividend payout. Following the earnings release and FY27 outlook update, the stock rose approximately by 7.70% to trade at AU$29.650.
Highlights:
Hospital segment momentum offsets softer Homecare growth and rising global cost pressures.
Higher dividend and FY27 guidance strengthen long-term investor confidence in earnings growth.
Tariff risks and expansion execution remain critical variables investors will closely monitor.
Strong Hospital Demand Drives Revenue Growth
Fisher & Paykel Healthcare reported FY26 operating revenue of NZ$2.31 billion, reflecting a 14% year-on-year increase, while net profit after tax rose 24% to NZ$468.5 million. The Hospital division remained the primary growth driver, with revenue increasing 18% to NZ$1.51 billion.
Management highlighted strong global demand for respiratory and acute care products, particularly hospital consumables. Growth continued despite softer respiratory illness admissions across major markets, supported by broader adoption of high-flow respiratory therapies.
Meanwhile, the Homecare division delivered comparatively slower growth. Revenue rose 8% to NZ$802.7 million, while OSA mask revenue increased 5% in constant currency, reflecting evolving competitive dynamics in the global sleep apnea market.
Gross margin improved to 63.7% in FY26, supported by manufacturing efficiencies and operational improvement initiatives. However, gross margins came under pressure from US tariffs applied to hospital products manufactured in New Zealand and exported to the United States.
Management expects tariff and geopolitical pressures to persist into FY27, with guidance including an estimated 50-basis-point net impact on gross margin. The company also invested NZ$235.5 million in research and development during FY26, supporting long-term innovation but potentially pressuring profitability if revenue growth moderates.
Balance Sheet and Cash Flow Support Expansion
Fisher & Paykel Healthcare ended FY26 with total assets of NZ$2.85 billion and shareholders’ equity of NZ$2.12 billion, while operating cash flow increased 21% to NZ$663.2 million, supporting future growth initiatives. The company continues expanding operations through developments in Auckland and China, while the proposed Karaka campus remains subject to rezoning approval. Delays, regulatory hurdles, or cost overruns could impact future returns.
Clinical Evidence Delivers Mixed Signals
Fisher & Paykel Healthcare highlighted positive findings from the SOHO clinical study, with high-flow nasal therapy reducing intubation rates among patients. However, the study did not demonstrate a reduction in 28-day mortality, leaving investors focused on further evidence supporting long-term treatment effectiveness and adoption trends.
Dividend Hike and FY27 Outlook Boost Confidence
The company declared a final dividend of NZ$0.33 per share, taking the total FY26 dividend to NZ$0.52 per share, up 22% year-on-year.
Looking ahead, management expects FY27 operating revenue between NZ$2.45 billion and NZ$2.57 billion, with projected net profit after tax ranging from NZ$500 million to NZ$550 million.
The outlook reinforces confidence in the company’s global respiratory care positioning, although investors are likely to remain focused on tariff impacts, execution risks, and the sustainability of margin expansion.
What Should Investors Do Next?
Investors are likely to monitor whether Fisher & Paykel Healthcare can maintain strong Hospital segment momentum while improving Homecare growth trends. Margin resilience, tariff exposure, and execution of large-scale expansion projects could become major performance drivers over the next 12 months.
For long-term investors, the company continues to offer exposure to defensive healthcare demand, expanding clinical adoption, and strong operational cash generation. However, rising geopolitical uncertainty, elevated investment spending, and slower growth in certain segments suggest that investors may also need to balance growth optimism with near-term operational risks.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
ASX 200 Health Care Stock Surges: Strong FY26 Profit, Dividend Growth, FY27 Outlook
Fisher & Paykel Healthcare Corporation Limited (ASX: FPH) reported strong FY26 results, supported by double-digit revenue growth, margin expansion, and a higher dividend payout. Following the earnings release and FY27 outlook update, the stock rose approximately by 7.70% to trade at AU$29.650.
Highlights:
Strong Hospital Demand Drives Revenue Growth
Fisher & Paykel Healthcare reported FY26 operating revenue of NZ$2.31 billion, reflecting a 14% year-on-year increase, while net profit after tax rose 24% to NZ$468.5 million. The Hospital division remained the primary growth driver, with revenue increasing 18% to NZ$1.51 billion.
Management highlighted strong global demand for respiratory and acute care products, particularly hospital consumables. Growth continued despite softer respiratory illness admissions across major markets, supported by broader adoption of high-flow respiratory therapies.
Meanwhile, the Homecare division delivered comparatively slower growth. Revenue rose 8% to NZ$802.7 million, while OSA mask revenue increased 5% in constant currency, reflecting evolving competitive dynamics in the global sleep apnea market.
Margin Expansion Continues Despite Tariff Pressure
Gross margin improved to 63.7% in FY26, supported by manufacturing efficiencies and operational improvement initiatives. However, gross margins came under pressure from US tariffs applied to hospital products manufactured in New Zealand and exported to the United States.
Management expects tariff and geopolitical pressures to persist into FY27, with guidance including an estimated 50-basis-point net impact on gross margin. The company also invested NZ$235.5 million in research and development during FY26, supporting long-term innovation but potentially pressuring profitability if revenue growth moderates.
Balance Sheet and Cash Flow Support Expansion
Fisher & Paykel Healthcare ended FY26 with total assets of NZ$2.85 billion and shareholders’ equity of NZ$2.12 billion, while operating cash flow increased 21% to NZ$663.2 million, supporting future growth initiatives. The company continues expanding operations through developments in Auckland and China, while the proposed Karaka campus remains subject to rezoning approval. Delays, regulatory hurdles, or cost overruns could impact future returns.
Clinical Evidence Delivers Mixed Signals
Fisher & Paykel Healthcare highlighted positive findings from the SOHO clinical study, with high-flow nasal therapy reducing intubation rates among patients. However, the study did not demonstrate a reduction in 28-day mortality, leaving investors focused on further evidence supporting long-term treatment effectiveness and adoption trends.
Dividend Hike and FY27 Outlook Boost Confidence
The company declared a final dividend of NZ$0.33 per share, taking the total FY26 dividend to NZ$0.52 per share, up 22% year-on-year.
Looking ahead, management expects FY27 operating revenue between NZ$2.45 billion and NZ$2.57 billion, with projected net profit after tax ranging from NZ$500 million to NZ$550 million.
The outlook reinforces confidence in the company’s global respiratory care positioning, although investors are likely to remain focused on tariff impacts, execution risks, and the sustainability of margin expansion.
What Should Investors Do Next?
Investors are likely to monitor whether Fisher & Paykel Healthcare can maintain strong Hospital segment momentum while improving Homecare growth trends. Margin resilience, tariff exposure, and execution of large-scale expansion projects could become major performance drivers over the next 12 months.
For long-term investors, the company continues to offer exposure to defensive healthcare demand, expanding clinical adoption, and strong operational cash generation. However, rising geopolitical uncertainty, elevated investment spending, and slower growth in certain segments suggest that investors may also need to balance growth optimism with near-term operational risks.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au